Breast cancer chemoprevention trials using the fine-needle aspiration model

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 7-12

  Kimler, Bruce F ^a   Fabian, Carol J ^b   Wallace, Dennis D ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Breast; Breast cancer development; Chemoprevention; Clinical trials; Cytology; EGFR; ER; Fine needle aspiration (FNA); Her 2 neu; High risk; P53; Ploidy; Risk assessment; Study design; Surrogate endpoint biomarker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; ANTINEOPLASTIC AGENT; EFLORNITHINE; PLACEBO; TUMOR MARKER;

ASPIRATION BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ARTICLE; BREAST; BREAST TUMOR; CLINICAL PROTOCOL; CLINICAL TRIAL; HYPERPLASIA; METABOLISM; METHODOLOGY; NEEDLE BIOPSY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CLINICAL PROTOCOLS; CLINICAL TRIALS; EFLORNITHINE; FEMALE; HUMANS; HYPERPLASIA; PLACEBOS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033649560     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<7::AID-JCB3>3.0.CO;2-W     Document Type: Review

References (18)

1. Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ. 1997. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials. Proc Soc Exp Biol Med 216:151-165.
2. Dhingra K. 1995. A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. J Cell Biochem 23(suppl):19-24.
3. Dhingra K, Vogel V, Sneige N, Sahin A, Aldaz M, Hortobagyi GN, Hittelman W. 1993. Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. J Cell Biochem 17(suppl G):37-43.
4. Fabian CJ, Kimler BF. 1997. Chemoprevention of breast cancer. Breast J 5:220-226.
5. Fabian C, Zalles C, Kamel S, McKittrick R, Moore W, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F, Jewell W. 1993. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem 17(suppl G): 153-160.
6. Fabian CJ, Zalles C, Kamel S, Kimler BF, McKittrick R, Tranin AS, Zeiger S, Moore WP, Hassanein RS, Simon C, Johnson N, Vergara G, Jewell WR, Lin F, Bhatia P, Chin T. 1994. Prevalence of aneuploidy, overexpressed ER and EGFR in random breast aspirates of women at high and low risk for breast cancer. Breast Cancer Res Treat 30:263-274.
7. Fabian CJ, Kamel S, Kimler BF, McKittrick R. 1995. Potential use of biomarkers in breast cancer risk assessment and chemoprevention trials. Breast J 1:236-242.
8. Fabian CJ, Kamel S, Zalles C, Kimler BF. 1996. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem 258:112-122.
9. Fabian CJ, Kamel S, Zalles C, Kimler BF. 1997a. Biomarkers predictive of short interval cancer development in high risk women. Breast J 3(suppl):42-48.
10. Fabian CJ, Zalles C, Kamel S, Kimler BF. 1997b. Short term development of breast cancer is predicted by fine needle aspiration cytology and cellular biomarkers. Proc Am Soc Clin Oncol 16:129a.
11. Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF. 1997e. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J Cell Biochem Suppl 28:101-110.
12. Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH. 1998. Models for early chemoprevention trials in breast cancer. Hematol Oncol Clin North Am 12:993-1017.
13. Kamel S, Zeiger S, Zalles C, Tawfik O, Simon G, Kimler BF, Fabian CF. 1998. p53 immunopositivity and gene mutation in a group of women at high risk for breast cancer. Breast J 4:396-404.
14. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P. 1993. Development of breast cancer chemopreventive drugs. J Cell Biochem 17(suppl G):2-13.
15. Masood S. 1995. Cytomorphology of fibrocystic change, high risk, and premalignant breast lesions. Breast J 1:210-221.
16. Masood S, Frykberg ER, McLellan GL, Scalapino MC, Mitchum DG, Bullard JB. 1990. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer 66:1480-1487.
17. O'Shaugnessy JA. 1996. Chemoprevention of breast cancer. JAMA 275:1349-1353.
18. Zalles C, Kimler BF, Kamel S, McKittrick R, Fabian CJ. 1995. Cytologic patterns in random aspirates from women at high and low risk for breast cancer. Breast J 1:343-349.